References

  • Albertus DS, et al.Randomised trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008;108(1):90-4.
  • Bay JO, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006; 119: 706-711.
  • Bay JO, et al. Association gemcitabine et docetaxel dans le traitement des sarcomes des tissus mous. Bull Cancer 2007; 94 (numero special) : S122-6.
  • Bertuzzi A, et al. High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study. J Clin Oncol 2002; 20 : 2181-2188.
  • Beumer JH, et al. Trabectedin (YondelisR, formerly ET-743), a mass balance study in patients with advanced cancer. Invest New Drugs 2005; 23(5): 429-36.
  • Beumer JH, et al. Metabolism of trabectedin (ET-743, YondelisR) in patients with advanced cancer. Cancer Chemother Pharmacol 2007;59(6):825-37.
  • Blay J-Y, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft- tissue sarcoma. Clin Cancer Res 2008; 14 (20): 6656-62.
  • Blay JY. Trabectedin: an emerging therapeutic option in soft tissue sarcoma. EJCMO 2009; 1(2): 1-7.
  • Bokemeyer C, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80:1221-7.
  • Bookman MA, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16(10):3345-52.
  • Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 1999;4(2):87-94.
  • Bosetti C, et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008;19(4):631-40.
  • Brady MS, et al. Radiation-associated sarcoma of bone and soft tissue. Arch Surg 1992; 127: 1379-1385.
  • Bramwell VHC, et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. The Cochrane Library 2003, Issue 3; Reprint John Wiley &Sons Ltd 2003; 1-19.
  • Brandon EF, et al. In-vitro cytotoxicity of ET-743 (Trabectedin, YondelisR), a marine anticancer drug, in theHepG2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005;16(9):935-43.
  • Bukowski RM, et al. The management of recurrent ovarian cancer. Seminars in Oncology 2007; 34 (2, Suppl 2):S1-S15.
  • Carter NJ, Keam SJ. Trabectedin. A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2010; 70 (3): 355-376.
  • Casado JA, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008; 7(5): 1309-18.
  • Casali PG, et al. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology 2010; 21 (Suppl 5): v198-v203.
  • Clark MA, et al. Soft tissue sarcomas in adults. N Engl J Med 2005; 353: 701-11. Coindre JM, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissues sarcomas. A study of 1240 patients from the French Federation of Cancer Centers Sarcoma Groups. Cancer 2001; 91: 1914-26.
  • Colombo N, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60(2):159-79.
  • Colombo N, Gore M. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 2007; 64 (2): 129-38.
  • Colombo N, et al. Int J Gynecol Cancer [Internet]. 2011 Oct [cited 2011 Sep 6];21(Suppl 3):[about 1 p.]. Available from: http://journals.lww.com/ijgc/Documents/ESGO%202011%20Abstracts.pdf.
  • Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004; 54: 94-109.
  • Cvetkovic RS, et al. Et-743. Drugs 2002;62(8):1185-92.
  • Damia G, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNArepair pathways. Int J Cancer 2001;92(4): 583-8.
  • Del Campo JM, et al. Phase II randomised study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h). to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol. 2009;20(11):1794-802.
  • Delaloge S, et al.Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients— preliminary evidence of activity. J Clin Oncol 2001; 19 (5):1248-55.
  • Demetri GD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-80.
  • Demetri GD, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma and leiomyosarcoma after failure or prior anthracyclines and ifosfamide: results of a randomised phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
  • Demetri GD, et al. Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide. ASCO 2009 J Clin Oncol; 27(15): 538, abstr 10509.
  • Demetri GD, et al. Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. ECCO-ESMO 2009 Eur J Cancer; 7(2): 590-591, abstr 09402.
  • Dinh P, et al. New therapies for ovarian cancer: cytotoxics and molecularly targeted therapies. Critical Reviews in Oncology/Hematology 2008;67: 103–112.
  • D’Incalci M, et al. The combination of YondelisR and cisplatin is synergistic against human tumour xenografts. Eur J Cancer 2003; 39(13):1920-6.
  • Du Bois A, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-viii12.
  • Duffaud F, et al. A FNCLCC French Sarcoma Group--GETO multicenter randomised phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol 2008;26 (suppl): abstr 10511.
  • Ebeling P, et al. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma- a single center experience. Onkologie 2008; 31:11-16.
  • EPAR Yondelis®. Assessment report for YondelisR. Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/yondelis/yondelis.htm.
  • Fayette J, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18(4):347-53.
  • Ferlay J, et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide.
  • Ferrandina G, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive
    or recurrent ovarian cancer. J Clin Oncol 2008;26(6):890-6.
  • Fleming. Gemcitabine/docetaxel-Welcome to a new standard. Gynecologic Oncology 2008;109: 313–315.
  • Forouzesh B, et al. Phase I and pharmacokinetic study of the marine-derivated DNA minor groove binder ET-743 on a weekly x 3 every-4-week schedule in patients with advanced solid malignancies. Proc AACR-NCI EORTC abstract. Eur J Cancer 2001;37 (Suppl.6): S32
  • Fung-Kee-Fung M, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14(5):195-208.
  • García-Carbonero R, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22(8):1480-90.
  • García-Carbonero R, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484-5492.
  • Gordon AN, et al. Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22.
  • Gordon AN, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95(1):1-8.
  • Greimel E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. European Journal of Cancer 2003;39: 1402–1408.
  • Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005; 65 (2): 167-178.
  • Hendriks HR, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, nonsmall-cell lung and ovarian cancer. Ann Oncol 1999;10(10):1233-40.
  • Hensley ML, et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. Gynecologic Oncology 2008;109: 323–328.
  • Herrero 2006, Herrero AB, et al. Cancer Res. 2006;66(16):8155-62.
  • Herrero AB, et al. Cross-Talk between Nucleotide Excision and Homologous Recombination DNA Repair Pathways in the Mechanism of Action of Antitumor Trabectedin. Cancer Research 2006;66(16):8155-8162.
  • Högber T, et al. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40(2-3):340-60.
  • Huinink WTB, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15: 2183-2193.
  • Huinink WTB, et al. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of Oncology 2004;15: 100–103.
  • Jemal A, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
  • Judson I, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXILR/CAELYXR) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 2001; 37:870-877.
  • Kavanagh J, et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 1995;13(7):1584-8.
  • Kaye SB. Management of partially platinum-sensitive relapsed ovarian Cancer. EJC Supplements 2008; 6:16-21.
  • Kaye SB, et al. Ann Oncol. 2011;22(1):49-58.
  • Krasner CN, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. British Journal of Cancer 2007; 97: 1618 – 1624.
  • Krasner CN, et al. Health related quality of life/patient reported outcomes in relapsed ovarian cancer: results from a randomised phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) vs doxorubicin alone. J Clin Oncol 2009; 27(suppl; abstr 5526):15s.
  • Kushner BH, et al. Dermoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996; 14: 1526-1531.
  • Le Cesne A, et al. Randomised Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676-2684.
  • Le Cesne A, et al. Impact of YondelisTM (trabectedin, ET-743) in the natural history of patients (pts) with pretreated advanced soft tissue sarcomas (PASTS): Long term follow-up results. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston 17 - 21 November 2003. Abstract A31”
  • Le Cesne A. New endpoints in evaluating advanced soft tissue sarcoma. Abstract presented at ECCO 2003.
  • Le Cesne A, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23 (3): 576-84.
  • Le Cesne A, et al. The new era of trabectedin in soft tissue sarcomas. EJHP Practice 2008; 14: 72-75.
  • Le Cesne A, et al. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs of Today 2009; 45 (6): 403-21.
  • Li WW, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001;7(9):2908-11.
  • Lorigan P, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25: 3144-3150.
  • Lorusso D, et al. Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer. J Chemother 2004;16 (Suppl 4):98-103.
  • Maki RG, et al. Randomised Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol 2007; 25:2755-2763.
  • Markman M, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9(3):389-93.
  • Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992;10(4):513-4.
  • Markman M, et al. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004; 31(Suppl 13): 91- 105.
  • McClain KL, et al. Association of Epstein–Barr virus with leiomyosarcomas in young people with AIDS. N Engl J Med 1995; 332:12-8.
  • McGuire WP, et al. Topotecan has substantial antitumour activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000;18(5):1062-7.
  • McMeekin S, et al. Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies. ASCO Annual Meeting, 28 May- 2 June, Orlando, Florida , 2007. Abstract 5579.
  • Meco D, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies.Cancer Chemother Pharmacol 2003;52(2):131-8.
  • Messersmith WA, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2008;63(1):181-8.
  • Minotti G, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumour activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
  • Monk BJ, Coleman RL. Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer From Platinum Doublets to Nonplatinum Doublets and Adding Antiangiogenesis Compounds. International Journal of Gynecological Cancer 2009; 19 (S2): S63-S67.
  • Monk BJ, et al. Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer. J Clin Oncol 2010; 28(19):3107-14.
  • Monk BJ, et al. J Clin Oncol. 2011 May;29(Suppl15):5046
  • NCCN Clinical Practice Guidelines in Oncology. Ovarian cancer. V.2.2010. Available at www.nccn.org
  • NICE Guidelines: National Institute for Health and Clinical Excellence, May 2005. Guidance TA 91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer.
  • Nielsen OS, et al. Effect of high dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group European Journal of Cancer 2000;36: 61-67.
  • Nielsen OS, et al. Metastatic soft tissue sarcoma in adults. Prognosis and treatment options. Am J Cancer 2003; 2(3):211- 221
  • Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005;15 (Suppl 1):3-11.
  • Papadopoulos KP, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumours. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings(Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement), 2006: 2029
  • Parmar MK, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVA R-2.2 trial. Lancet 2003;361(9375):2099-106.
  • Patel SR, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21 (3): 317-21.

  • Perez-Lopez ME, et al. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 2007;18(5):611-7.
  • Pfisterer J, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVA R, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24(29):4699-707.
  • Pignata S, Monfardini S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer 2000;36(7):817-20.
  • Pommier Y, et al. DNA sequence and structure-selective alkylation of guanineN2 in the DNA minor groove by ecteinascidin 743, a potent antitumour compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996; 35(41): 13303-9.
  • Poveda A. Gemcitabine in patients with ovarian cancer. Cancer Treat Rev 2005;31 (Suppl 4):S29-37.
  • Poveda A. Management of recurrent ovarian cancer with systemic therapy. EJC Supplements 2007; 5 (1):29-36.
  • Poveda A, et al. J Clin Oncol. 2011 May;29(Suppl15):5067
  • Poveda A, et al. Ann Oncol. 2011;22(1):39-48.
  • Puchalski TA, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002;50(4):309-19.
  • Pujade-Lauraine, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010;28(20): 3323-3329.
  • Reid JM, et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002;8(9):2952-62.
  • Romero, et al. Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC). J Clin Oncol 2010; 28(15): 420, abstr 5121.
  • Ryan DP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72- hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7(2):231-42.
  • Salzberg M, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005;68(4-6):293-8.
  • Santoro A, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomised study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537-1545.

  • Schöffski P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opinion 2008; 9 (9): 1609-1618.
  • Scotlandi K, et al . Effectiveness of Ecteinascidin-743 against drug-sensitive and –resistant bone tumour cells. Clin Cancer Res 2002;8(12): 3893-903.
  • Sessa C, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23(9):1867-74.
  • Sessa C, Cresta S, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer. 2009;45(12):2116-22.
  • Sessa C, Perotti A, et al . Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009; 45 (7): 1153-61.
  • Seynaeve C, Verweij J. High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol 1999; 26:119- 133.
  • Sleifjer S, Verweij J. Trial Methodology in Soft Tissue Sarcomas; the ‘One Plus One is Three or Zero’ Phenomenon. Onkologie 2008; 31:6-8.
  • Soares DG, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. PNAS 2007; 104(32): 13062-13067.
  • Stojadinovic A, et al. Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables. J Clin Oncol 2002; 20:4344-4352.
  • Taamma A, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumours. J Clin Oncol 2001;19(5):1256-65.
  • Takahashi N, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001;7(10):3251-7.
  • Takahashi N, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Research 2002; 62: 6909-6915.
  • Takebayashi Y, Goldwasser F, et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001;7(1):185-91.
  • Takebayashi Y, Pourquier P, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcriptioncoupled nucleotide-excision repair. Nat Med 2001;7(8):961-6.
  • Temple R, Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiology and Drug Safety 2006;15:241-243.
  • Tevecchio M, et al. Role of homologous recombination in trabectedin-induced DNA damage. European Journal of Cancer 2008; 44(4): 609-618.
  • Therasse P, et al. RECIST vs. WHO: Prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. European Journal of Cancer 2005; 41:1426–1430.
  • Trotti A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment.Seminars in Radiation Oncology 2003;13 (3): 176-181.
  • Twelves C, et al. Phase I and pharmacokinetic study of YondelisR (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patientswith solid tumours. Eur J Cancer 2003;39(13):1842-51.
  • Valoti G, et al. Ecteinascidin- 743, a New Marine Natural Product with Potent Antitumour Activity on Human Ovarian Carcinoma Xenografts1. Clin Can Research 1998;(4):1977-83.
  • Van Glabbeke M, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. European Journal of Cancer 2002;38: 543–549.
  • Van Kesteren C, et al. Pharmacokinetics and pharmacodynamics of the novel marine derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000;6(12):4725-32.
  • Van Kesteren C, et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 2002;13(4):381-93.
  • Van Oosterom AT, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. European Journal of Cancer 2002;38: 2397–2406.
  • Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 2003;89 (Suppl 3):S23-8.
  • Vasey PA, et al. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Annals of Oncology 2005; 16 (suppl 1): i13-i15.
  • Vergote, et al. Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. Eur J Cancer 2009; 7(2):458, abstr P8028.
  • Vergote I, et al. Int J Gynecol Cancer [Internet]. 2011 Oct [cited 2011 Sep 6];21(suppl 3)
  • Vermorken JB. Second-line randomised trials in epithelial ovarian cancer. Int J Gynecol Cancer 2008: 18 (Suppl 1):59-66.
  • Vermorken JB, et al. Patient-reported outcomes in patients with relapsed, platinum-sensitive ovarian cancer (ROC): Results from a large randomized phase III trial. Int J Gynecol Cancer 2010; 20(2): Abs 00458.
  • Verweij J, et al. Randomised phase II study of docetaxel versus doxorubicin in first and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18:2081-2086.
  • Vidal L, et al. Phase I combination study of trabectedin and carboplatin in advanced solid tumours [abstract no. 396P]. Ann Oncol 2004; 15 Suppl 3: iii106.
  • Villalona-Calero MA, et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8(1):75-85.
  • Von Mehren M, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008;19(10):1802-9.
  • Yondelis® Summary of Products Characteristics. Available at: here
  • Yovine A, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22 (5): 890-9.
  • Zahm SH, Fraumeni JF. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24:504-514.
  • Zewail-Foote M, et al. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumour agent. Chem Biol 2001; 8(11):1033-49.